Pseudomonas aeruginosa and post-tracheotomy bacterial respiratory tract infection readmissions

Pediatric Pulmonology

Volumn 52, Issue 9, 2017, Pages 1212-1218

  Russell, Christopher J ^a,b   Simon, Tamara D ^c,d   Mamey, Mary R ^a   Newth, Christopher J L ^a,b   Neely, Michael N ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

bacterial; child; hospitalized; pediatric; pneumonia; readmission; tracheitis

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CHILD; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; ETHNICITY; FEMALE; HEALTH INSURANCE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; INFANT; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; TRACHEITIS; TRACHEOTOMY; NEWBORN; ODDS RATIO; PRESCHOOL CHILD; PSEUDOMONAS INFECTION; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TRACHEOSTOMY;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LENGTH OF STAY; LOGISTIC MODELS; MALE; ODDS RATIO; PATIENT DISCHARGE; PATIENT READMISSION; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TRACHEITIS; TRACHEOSTOMY; TRACHEOTOMY;

EID: 85018339630     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23716     Document Type: Article

References (33)

1. AHRQ. Agency for healthcare research and quality. HCUP KID database 2012.
2. AHRQ. Preventable hospitalizations: a window into primary and preventive care. 2000.
3. Zhu H, Das P, Roberson DW, et al. Hospitalizations in children with preexisting tracheostomy: a national perspective. Laryngoscope 2015; 125:462–468.
4. Russell CJ, Mack WJ, Schrager SM, Wu S. Care variations and outcomes for children hospitalized with bacterial tracheostomy-associated respiratory infections. Hosp Pediatr 2017; 7:16–23.
5. Lewis CW, Carron JD, Perkins JA, Sie KC, Feudtner C. Tracheotomy in pediatric patients: a national perspective. Arch Otolaryngol Head Neck Surg 2003; 129:523–529.
6. Edwards JD, Houtrow AJ, Lucas AR, et al. Children and young adults who received tracheostomies or were initiated on long-term ventilation in PICUs. Pediatr Crit Care Med 2016; 17:e324–e334.
7. Meier JD, Valentine KJ, Hagedorn C, et al. Emergency department use among children with tracheostomies: avoidable visits. J Pediatr Rehabil Med 2015; 8:105–111.
8. McCaleb R, Warren RH, Willis D, Maples HD, Bai S, O'Brien CE. Description of respiratory microbiology of children with long-Term tracheostomies. Respir Care 2016; 61:447–452.
9. Zemanick ET, Emerson J, Thompson V, et al. Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatr Pulmonol 2015; 50:42–48.
10. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995; 48:1041–1049.
11. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12:158–161.
12. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. 2001; 32:277–287.
13. Pamukcu A, Bush A, Buchdahl R. Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995; 19:10–15.
14. Cogen J, Emerson J, Sanders DB, et al. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol 2015; 50:763–770.
15. Berry JG, Graham DA, Graham RJ, et al. Predictors of clinical outcomes and hospital resource use of children after tracheotomy. Pediatrics 2009; 124:563–572.
16. Berry JG, Graham RJ, Roberson DW, et al. Patient characteristics associated with in-hospital mortality in children following tracheotomy. Arch Dis Child 2010; 95:703–710.
17. Cline JM, Woods CR, Ervin SE, Rubin BK, Kirse DJ. Surveillance tracheal aspirate cultures do not reliably predict bacteria cultured at the time of an acute respiratory infection in children with tracheostomy tubes. Chest 2012; 141:625–631.
18. Pennington A, Dobies CG. PHIS Description when referenced as data source. Volume 20142014.
19. Jenkins KJ, Gauvreau K, Newburger JW, Spray TL, Moller JH, Iezzoni LI. Consensus-based method for risk adjustment for surgery for congenital heart disease. J Thorac Cardiovasc Surg 2002; 123:110–118.
20. Barnhart DC, Hall M, Mahant S, et al. Effectiveness of fundoplication at the time of gastrostomy in infants with neurological impairment. JAMA Pediatr 2013; 167:911–918.
21. Srivastava R, Berry JG, Hall M, et al. Reflux related hospital admissions after fundoplication in children with neurological impairment: retrospective cohort study. BMJ 2009; 339:b4411.
22. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167:841–849.
23. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998; 25:88–92.
24. Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009; 33:305–311.
25. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991; 338:725–726.
26. Lee TW. Eradication of early Pseudomonas infection in cystic fibrosis. Chron Respir Dis 2009; 6:99–107.
27. Mayer-Hamblett N, Kronmal RA, Gibson RL, et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012; 47:125–134.
28. Lu S, Kuo DZ. Hospital charges of potentially preventable pediatric hospitalizations. Acad Pediatr 2012; 12:436–444.
29. Berry JG, Hall M, Dumas H, et al. Pediatric hospital discharges to home health and postacute facility care: a national study. JAMA Pediatr 2016.
30. Buu MC, Sanders LM, Mayo JA, Milla CE, Wise PH. Assessing differences in mortality rates and risk factors between Hispanic and non-hispanic patients with cystic fibrosis in california. Chest 2016; 149:380–389.
31. Oster ME, Strickland MJ, Mahle WT. Racial and ethnic disparities in post-operative mortality following congenital heart surgery. J Pediatr 2011; 159:222–226.
32. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117:e817–e820.
33. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009; 154:514–520. e514.